Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R2-GOD in Relapsed/Refractory DLBCL
NCT03795571Phase 1Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Maximum Tolerated Dose and Dose Limiting Toxicity at 28 days. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03795571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795571.